ישראל - עברית - Ministry of Health

astrazeneca (israel) ltd - gefitinib - טבליות מצופות פילם - gefitinib 250 mg - gefitinib - gefitinib - iressa is indicated as monotherapy for the continued treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of both platinum-based and docetaxel chemotherapies who are benefiting or have benefited from iressa. results from two large controlled randomized trials in first-line treatment of non-small cell lung cancer showed no benefit from adding iressa to doublet platinum-based chemotherapy.iressa is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating mutations of egfr-tk.

ישראל - עברית - Ministry of Health

astra zeneca (israel) ltd - gefitinib - טבליות מצופות פילם - gefitinib 250 mg - gefitinib

ישראל - עברית - Ministry of Health

teva israel ltd - gefitinib - טבליות מצופות פילם - gefitinib 250 mg - gefitinib

ישראל - עברית - Ministry of Health

k.s.kim international (sk- pharma) ltd., israel - gefitinib - טבליות מצופות פילם - gefitinib 250 mg - gefitinib

ישראל - עברית - Ministry of Health

novartis israel ltd - gefitinib - טבליות מצופות פילם - gefitinib 250 mg

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 150 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

ישראל - עברית - Ministry of Health

roche pharmaceuticals (israel) ltd - erlotinib as dihydrochloride - טבליות מצופות פילם - erlotinib as dihydrochloride 100 mg - erlotinib - erlotinib - tarceva is indicated for the treatment of patients with locally advanced or metastatic non - small cell lung cancer after failure of at least one prior chemotherapy regimen. tarceva is indicated in combination with gemcitabine for the first-line treatment of patients with locally advanced unresectable or metastatic pancreatic cancer.tarceva® monotherapy is indicated for the maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with egfr activating mutations.

ישראל - עברית - Ministry of Health

boehringer ingelheim israel ltd. - afatinib as dimaleate - טבליות מצופות פילם - afatinib as dimaleate 20 mg - afatinib

ישראל - עברית - Ministry of Health

boehringer ingelheim israel ltd. - afatinib as dimaleate - טבליות מצופות פילם - afatinib as dimaleate 30 mg - afatinib

ישראל - עברית - Ministry of Health

boehringer ingelheim israel ltd. - afatinib as dimaleate - טבליות מצופות פילם - afatinib as dimaleate 40 mg - afatinib